Responses
Pathophysiology/Complications
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
Compose a Response to This Article
Other responses
No responses have been published for this article.